Indian Generics Press For Compulsory Licenses Concerns Brand Makers
This article was originally published in PharmAsia News
Executive Summary
Multinational drug makers are voicing concerns about moves in India to impose compulsory licenses that would free others, mainly Indian manufacturers, to make generic copies of their drugs. Indian generics makers are looking into the possibility of using World Trade Organization provisions that allow patents to be overridden during medical emergencies or when cheaper drugs can be exported to least-developed nations. The Trade-Related Aspects of Intellectual Property Rights provision allows patent holders to receive "adequate remuneration." Natco Pharma already has requested compulsory licenses on two cancer drugs, a move that could become part of a trend. A Pfizer official says such a move "would be a clear disregard of Indian patent laws." (Click here for more
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.